跳至主要内容
临床试验/CTRI/2021/09/036767
CTRI/2021/09/036767尚未招募3 期

A prospective study to investigate peri-operative management of patients with severe haemophilia A who are on Emicizumab therapy and are undergoing elective major surgeries - Not applicable

Roche Products India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age >2 years <60 years, severe haemophilia A with or without inhibitor, elective major surgery for any indication except neurosurgical or invasive ophthalmic procedures.

排除标准

  • Emergency surgery, severe organ dysfunction, coagulopathy (DIC) requiring multiple blood product support, patients requiring antiplatelet agents, patients on any other on-going trial, history of previous thromboembolic episode, previous hypersensitivity to any of the study drugs.

研究者

相似试验